Mobile

A 16 WEEK OPEN-LABEL OUTPATIENT, RANDOMIZED, PARALLEL STUDY ASSESSING THE IMPACT OF TWO DIFFERENT INITIAL DOSE PRESCRIPTIONS FOR DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL IN PATIENTS W...

Update Il y a 4 ans
Reference: EUCTR2006-007034-36

A 16 WEEK OPEN-LABEL OUTPATIENT, RANDOMIZED, PARALLEL STUDY ASSESSING THE IMPACT OF TWO DIFFERENT INITIAL DOSE PRESCRIPTIONS FOR DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE POORLY CONTROLLED ON A COMBINATION OF TWO OR MORE ORAL AGENTS

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is noninferior compared to the standard weight-based formula.

Inclusion criteria

  • Diabetes Mellitus, Type 2

Links